Core Insights - Baxter International Inc. is currently among the Top 15 Lowest P/E Ratios of the S&P 500 for 2025, indicating a potentially undervalued stock [1] - Analysts have a consensus Hold recommendation for Baxter, with a one-year average share price target of $23.80, suggesting an upside potential of 28% [4] Financial Adjustments - Morgan Stanley analyst Patrick Wood has reduced the price target for Baxter from $19 to $15 while maintaining an Underweight rating [1] - Argus Research downgraded Baxter on October 31, citing a significant dividend reduction expected to drive an annual cash flow boost of $300 million or more, aimed at strengthening the balance sheet [3] Market Position and Performance - The company is well-positioned in the medical technology sector due to favorable trends in hospital spending and key product launches [2] - Baxter's stock has faced challenges, declining 36% year to date [4] - Concerns have been raised regarding the weak outlook for Baxter's IV fluid solutions business [4]